全球消除HBV母婴传播的进展与挑战OA北大核心CSTPCD

At present,there are policies for hepatitis B testing in 89.8%of countries and regions around the world.In 2022,the global hepatitis B vaccine birth dose coverage reached 45%,while the third-dose coverage reached 85%.Approximately 3%of pregnant women with high viral loads have received antiviral therapy,and the prevalence rate of HBsAg is about 0.7%among children aged≤5 years.While significant progress has been made in various countries towards eliminating mother-to-child transmission of hepatitis B virus(HBV),there are still large gaps across countries and numerous challenges.There are differences in the prevalence of hepatitis B,vaccination,and access to antiviral drugs across the globe,and in addition,the factors such as insufficient laboratory testing capacity and difficulties in ensuring sustained access to treatment among pregnant and parturient women with HBV infection pose obstacles to eliminating the mother-to-child transmission of HBV.